Dyspnea - Pipeline Review, H1 2012

Global Markets Direct, June 2012, Pages: 27

Dyspnea – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Dyspnea - Pipeline Review, H1 2012', provides an overview of the Dyspnea therapeutic pipeline. This report provides information on the therapeutic development for Dyspnea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dyspnea. 'Dyspnea - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dyspnea.
- A review of the Dyspnea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dyspnea pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Dyspnea.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dyspnea pipeline depth and focus of Dyspnea therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Dyspnea Therapeutic Products under Development, Key Players in Dyspnea Therapeutics, Dyspnea Pipeline Overview, Dyspnea Pipeline, Dyspnea Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dyspnea Overview
Therapeutics Development
An Overview of Pipeline Products for Dyspnea
Dyspnea Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Dyspnea Therapeutics – Products under Investigation by Universities/Institutes
Dyspnea – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Sertraline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Furosemide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Furosemide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sertraline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Morphine + Coloxyl + Senna - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Morphine + Clonazepam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dyspnea Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Dyspnea, H1 2012
Products under Development for Dyspnea – Comparative Analysis, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Dyspnea Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Dyspnea, H1 2012
Products under Development for Dyspnea – Comparative Analysis, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Dyspnea - Pipeline Review, H2 2012
• Dyspnea Global Clinical Trials Review, H1, 2012
• Rhinitis - Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Rotavirus Infections – Pipeline Review, H1 2013
• Febrile Neutropenia - Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Burns - Pipeline Review, H1 2013
• Bronchopulmonary Dysplasia - Pipeline Review, H1 2013
• Alzheimer's Disease – Pipeline Review, H1 2013